A
Alumis Inc. (ALMS)
24.80
0.00 (0.00%)
Get all premium features to the best stock analysis tool
24.80
0.00 (0.00%)
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Mr. Jack Danilkowicz | Chief Commercial Officer |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer |
| Mr. Kolbot By Ph.D. | Senior VP & Head of Technical Operations |
| Mr. Mark Bradley | Chief Development Officer |
| Mr. Martin Babler Ph.D. | President, CEO & Chairman |
| Ms. Grace Halteh | Senior VP & Head of Quality and Regulatory |
| Ms. Sanam Pangali J.D. |
| Date | Type | Document |
|---|---|---|
| 2026-03-19 | 10-K | alms-20251231x10k.htm |
| 2026-01-30 | S-8 | tm263983d1_s8.htm |
| 2026-01-09 | 8-K | tm262561d1_8k.htm |
| 2026-01-02 | 8-K | tm2534587d2_8k.htm |
| 2025-11-13 | 10-Q | alms-20250930x10q.htm |
| 2025-09-03 | 8-K | tm2525079d1_8k.htm |
| 2025-08-15 | CORRESP | filename1.htm |
| 2025-08-13 | 10-Q | alms-20250630x10q.htm |
| 2025-08-04 | 8-K | tm2521941d1_8k.htm |
| 2025-07-03 | S-3 | tm2519224-2_s3.htm |
| Chief Legal Officer & Corporate Secretary |